Bromocriptine SRO in Parkinson's disease: Preliminary results

F. Stocchi; M. F. De Pandis; G. Fabbrini; S. Ruggieri; P. Bocciarelli; A. Agnoli

Bromocriptine SRO in Parkinson's disease: Preliminary results

F. Stocchi, M. F. De Pandis, G. Fabbrini, S. Ruggieri, P. Bocciarelli, A. Agnoli

Research output: Contribution to journal › Article › peer-review

Abstract

Bromocriptine SRO is a new galenic preparation which allows a slow release of the drug and the maintaining of more stable plasma levels of drug. Two groups of patients with a diagnosis of Parkinson's disease, 7 'de novo' and 8 with fluctuations in motor performance were studied. Patients were followed up to three months by means of clinical ratings every month. Results of the study show an improvement of disability in the 'de novo' and an increase in the number of hours spent in the 'on' passage with respect to 'off' phase in the fluctuating patients. No significant side effects were recorded.

Original language	English
Pages (from-to)	35-40
Number of pages	6
Journal	New Trends in Clinical Neuropharmacology
Volume	4
Issue number	2
Publication status	Published - 1990

ASJC Scopus subject areas

Clinical Neurology
Pharmacology

Fingerprint Dive into the research topics of 'Bromocriptine SRO in Parkinson's disease: Preliminary results'. Together they form a unique fingerprint.

Cite this

@article{24f6eab702a84a7394ac28f7fdfebb93,

title = "Bromocriptine SRO in Parkinson's disease: Preliminary results",

abstract = "Bromocriptine SRO is a new galenic preparation which allows a slow release of the drug and the maintaining of more stable plasma levels of drug. Two groups of patients with a diagnosis of Parkinson's disease, 7 'de novo' and 8 with fluctuations in motor performance were studied. Patients were followed up to three months by means of clinical ratings every month. Results of the study show an improvement of disability in the 'de novo' and an increase in the number of hours spent in the 'on' passage with respect to 'off' phase in the fluctuating patients. No significant side effects were recorded.",

author = "F. Stocchi and {De Pandis}, {M. F.} and G. Fabbrini and S. Ruggieri and P. Bocciarelli and A. Agnoli",

year = "1990",

language = "English",

volume = "4",

pages = "35--40",

journal = "New Trends in Clinical Neuropharmacology",

issn = "0393-5345",

number = "2",

}

TY - JOUR

T1 - Bromocriptine SRO in Parkinson's disease

T2 - Preliminary results

AU - Stocchi, F.

AU - De Pandis, M. F.

AU - Fabbrini, G.

AU - Ruggieri, S.

AU - Bocciarelli, P.

AU - Agnoli, A.

PY - 1990

Y1 - 1990

N2 - Bromocriptine SRO is a new galenic preparation which allows a slow release of the drug and the maintaining of more stable plasma levels of drug. Two groups of patients with a diagnosis of Parkinson's disease, 7 'de novo' and 8 with fluctuations in motor performance were studied. Patients were followed up to three months by means of clinical ratings every month. Results of the study show an improvement of disability in the 'de novo' and an increase in the number of hours spent in the 'on' passage with respect to 'off' phase in the fluctuating patients. No significant side effects were recorded.

AB - Bromocriptine SRO is a new galenic preparation which allows a slow release of the drug and the maintaining of more stable plasma levels of drug. Two groups of patients with a diagnosis of Parkinson's disease, 7 'de novo' and 8 with fluctuations in motor performance were studied. Patients were followed up to three months by means of clinical ratings every month. Results of the study show an improvement of disability in the 'de novo' and an increase in the number of hours spent in the 'on' passage with respect to 'off' phase in the fluctuating patients. No significant side effects were recorded.

UR - http://www.scopus.com/inward/record.url?scp=0025609809&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025609809&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0025609809

VL - 4

SP - 35

EP - 40

JO - New Trends in Clinical Neuropharmacology

JF - New Trends in Clinical Neuropharmacology

SN - 0393-5345

IS - 2

ER -

Bromocriptine SRO in Parkinson's disease: Preliminary results

Abstract

ASJC Scopus subject areas

Other files and links

Cite this